Xuanzhu Biotech-B (02575): Innovative drug Anjiuwei successfully renewed and included in the national basic medical insurance drug list for 2025.

Zhixun Finance APP News, Xuanzhu Biology-B (02575) announced that, after a simple medical insurance renewal with the National Medical Security Administration of China (National Medical Insurance Bureau), the innovative drug Anilarazole Sodium Enteric-coated Tablets (trade name: Anjiuwei), independently developed by the company, will continue to be included in the new version of the National Basic Medical Insurance, Maternity Insurance, and Work-related Injury Insurance Drug Catalog (2025 National Basic Medical Insurance Drug Catalog) that will take effect from January 1, 2026.